Immunoglobulin E specific for peanut allergens (Peanut-specific IgE)

Immunoglobulin E (IgE) specific for peanut allergens is the primary mediator of the rapid-onset allergic immune response in sensitized individuals. These antibodies are produced by B cells and plasma cells in response to specific peanut proteins, such as Ara h 1, Ara h 2, and Ara h 3, which are recognized as foreign threats (Sampson et al., 2018, J Allergy Clin Immunol). Peanut-specific IgE circulates in the blood and binds with high affinity to FcεRI receptors on the surface of mast cells and basophils. When a sensitized individual is exposed to peanuts, the allergens cross-link these surface-bound IgE molecules, triggering the explosive release of inflammatory mediators like histamine and leukotrienes, which can lead to life-threatening anaphylaxis (Galli & Tsai, 2012, Nature Medicine). On B cells, membrane-bound IgE serves as a component of the B-cell receptor, facilitating allergen uptake and the maintenance of allergic memory. Therapeutic strategies targeting this molecule include anti-IgE monoclonal antibodies that sequester free IgE to prevent mast cell priming and allergen-specific immunotherapy designed to desensitize the immune system by shifting the balance toward protective IgG4 antibodies (Wood et al., 2024, NEJM).

Other names

Peanut sIgEAllergen-specific IgEAnti-peanut IgEPeanut-reactive IgE

Monoclonal antibodies like Omalizumab bind to the Cε3 domain of circulating IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils. This sequestration reduces the density of IgE-FcεRI complexes on the cell surface and subsequently downregulates receptor expression, raising the threshold for allergen-induced activation (Wood et al., 2024, NEJM). Other agents like Quilizumab target the M1-prime segment of membrane-bound IgE on B cells to deplete IgE-switched B cells and prevent the production of new peanut-specific IgE (Gauvreau et al., 2014, J Allergy Clin Immunol).